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Abstract 
In most tropical areas, pregnant women are at increased risk of malaria, as a consequence of the massive sequestra-
tion of parasitized red blood cells in the placenta. The placenta plays a key role in embryonic and fetal development 
as well as in maternal-fetal exchanges, and pregnancy-associated malaria may alter selected placenta functions that 
lead to stillbirth and low birth weight. Although there are several tools (blood smear examination, RDT, PCR) to diag-
nose malaria infection during pregnancy, there is currently no test to assess placenta dysfunction in the framework of 
pregnancy-associated malaria. Pregnancy-associated malaria shares many features with preeclampsia, an extensively 
studied disease. Various biomarkers associated with placental dysfunction have been identified as associated with 
preeclampsia. Several of these are inflammatory markers that lack of specificity. A few seem more specific of placenta 
dysfunction, including s-endoglin and sFlt1, increased in the peripheral blood during preeclampsia. The predictive 
value of these biomarkers should be studied in the context of pregnancy-associated malaria to evaluate their use-
fulness in identifying placental dysfunction during malaria. These biomarkers should be considered to improve the 
diagnosis of placental dysfunction during malaria and pregnant women monitoring.
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Background
Placenta and syncytiotrophoblast cells
Placenta is a new transitional organ essential to the pres-
ervation of pregnancy and fetal development. It ensures 
maternal-fetal exchanges and is also involved in mater-
nal tolerance of feto-paternal antigens. In some species, 
including human, the placenta exerts hormonal functions 
that are required for the maintenance of gestation and 
fetal well-being.
During pregnancy, a vascular shunt is formed, and 
maternal blood crosses the myometrium via utero-
placental arteries to invade the intervillous space under 
maternal blood pressure. Throughout pregnancy, syn-
cytiotrophoblasts (ST) evolves towards cellular death by 
apoptosis in the intervillous space. Their renewal is a con-
tinuous phenomenon, and is more pronounced in case of 
placental suffering. ST represent the first mother-fetal 
interface, and fulfil many functions. They also have a 
major endocrine role by participating in the steroidogen-
esis and in the synthesis of pregnancy-specific hormones, 
human chorionic gonadotrophin (hCG) and human pla-
cental lactogen (hPL). hCG is a placentation early marker, 
and a functionality marker [1, 2]. Finally, the ST have an 
immuno-modulation function by allowing maternal tol-
erance in front of the semi-allogenic transplant of the 
feto-placental unit.
Malaria infection
Plasmodium falciparum infection is contracted from an 
anopheles bite by injection of sporozoites, which quickly 
begin an intra-hepatocytic maturation phase. Merozo-
ites are released from the hepatocyte and invade eryth-
rocytes, beginning a 48-h long erythrocytic cycle during 
which the parasite goes through several morphological 
stages, from ring to trophozoite and schizont [3]. The 
key step during this erythrocytic cycle is the important 
trafficking of proteins. Indeed, P. falciparum-derived pro-
teins are successively expressed, some are exported, and 
presented at the surface of infected erythrocytes (iE) cell 
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membrane, leading to physical and morphological altera-
tions of iE. iE shape and deformability are modified, and 
electron dense protrusions, the knobs, appear at their 
surface. Knob structure involves complex interactions 
between parasite proteins and the iE membrane cytoskel-
eton. Knobs are involved in the export of variant surface 
antigens (VSAs), such as P. falciparum erythrocyte mem-
brane protein-1 (PfEMP-1), mediating the adhesion of 
iE to endothelial cell receptors, a phenomenon required 
for the completion of the erythrocytic cycle. PfEMP-1 is 
a highly variable protein, allowing the parasite to escape 
host immunity, and to specifically adhere to endothelial 
cells or to deep organs, such as the surface of the ST at 
the intervillous spaces of the placenta. This adhesion 
requires a specific receptor on the endothelial cell, which 
in the case of the ST is chondroitin sulphate A (CSA) 
[4]. By presenting these ligands, the parasite allows host 
immune recognition of the altered iE surface. To evade 
the immune response, these proteins display extensive 
antigenic variation, concurrently changing the receptor 
recognition, and then the tissue tropism of the iE [5]. One 
member of the PfEMP-1 family, VAR2CSA, is specific of 
parasites encountered during pregnancy. Only the para-
sites expressing the VAR2CSA variant are able to seques-
ter in the placenta and those parasites cannot bind to 
receptors expressed elsewhere, therefore, they have never 
been able to multiply in the host before the first preg-
nancy, and no immune response against VAR2CSA exists 
[6]. The binding is strengthened by the attraction of their 
opposite charges and resists the maternal blood flow [7]. 
The result is the adherence and accumulation of iE in the 
intervillous space. This parasite adhesion to placental 
receptor CSA is the initiator of the immune response to 
CSA-binding iE, fundamental to the pregnancy-associ-
ated malaria (PAM) pathogenesis.
Pregnancy‑associated malaria
The sequestration of numerous iE in the placenta is 
responsible for inflammatory damages with fibrinoid 
deposits at its surface, similar to chronic intervillitis [8]. 
These damages may alter the placenta functions and lead 
to delayed fetal growth. Malaria infection has pro-inflam-
matory effects, in particular on infected placentas where 
appear an oxidative stress and fibrin deposits. iE seques-
tration leads to acute vascular modifications of placen-
tal villi, reducing the available surface for feto-placental 
exchanges. This decrease may be correlated with intra-
uterine growth retardation [9, 10]. The blood flow modi-
fications by the accumulation of iEs in the intervillous 
spaces originate ST hypoxia and angiogenesis deregula-
tion. The long-term placental infringements may result 
in low birth weight, in utero fetal death, and important 
perinatal morbi-mortality [11]. Abnormal intra-uterine 
environment (exchange defect and hypoxemia) affects 
the cognitive, metabolic and anthropometric develop-
ment of the fetus, which may lead to a greater risk of dis-
ease for the newborn child [12]. In P. falciparum-infected 
pregnant women, ultrasound studies reported intra-uter-
ine fetal growth restriction, and Doppler analysis showed 
fetal brain vasodilatation, witness of hypoxia [13].
Current recommendations for PAM diagnosis 
and prevention
For pregnant women living in moderate to high malaria 
transmission areas, the World Heath Organization 
(WHO) recommends the use of long-lasting insecti-
cide-impregnated bed nets and intermittent preventive 
treatment (IPT) which consists of a curative regimen 
of sulfadoxine-pyrimethamine, from the second half of 
pregnancy, during each antenatal visit providing those 
are spaced by at least one month. This prevention allows 
to reduce the number of malaria attacks during preg-
nancy, the placental sequestration, and the fetal conse-
quences [14]. Nevertheless, IPT is only partially effective 
in preventing malaria infection during pregnancy and 
its consequences, due to several reasons, including the 
lack of coverage of the first trimester by IPT, and the 
high prevalence of parasite resistance to sulfadoxine-
pyrimethamine in most malaria endemic areas.
Women living in areas of stable malaria present even 
(or non-existent) symptoms that do not allow predicting 
placental infringement. In clinical practice, the biological 
diagnosis of malaria relies on thick blood smear micro-
scopic examination and rapid diagnostic test (RDT). The 
thick smear allows to estimate the parasite density in the 
maternal peripheral blood, but does not reveal the level 
of placental parasite sequestration. RDT may be a better 
diagnostic tool for use in pregnant women, as P. falcipa-
rum sequesters in the placenta and, therefore, may not 
be present in the peripheral blood, producing false-neg-
ative results of the blood smear. For the WHO, the RDT 
is now the reference test [15]. However, the evidence of 
the presence of parasites in peripheral blood (either by 
blood smear or RDT) does not inform the clinician about 
the importance of placental sequestration, nor about the 
current placental function. In addition, both thick blood 
smear examination and RDTs suffer from a lack of sen-
sitivity, and the molecular diagnosis by PCR allows to 
evidence as many as 2–4 times more women infected by 
P. falciparum experiencing a so-called sub-microscopic 
infection. These sub-microscopic infections are also 
associated with poor pregnancy outcomes, as maternal 
anaemia, premature birth and low birth weight are more 
frequent [16]. Currently, no tool is available in endemic 
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areas to identify suffering placentas. Such a tool would 
be of great interest, allowing to identify patients at risk 
of PAM complications, such as IUGR. A curative treat-
ment could potentially be initiated, and an observation 
of the fetus suffering from the defective functions of the 
placenta should be initiated.
Immunology during pregnancy and PAM
An immunological balance during pregnancy allows the 
tolerance of the semi-allogenic transplant, represented 
by the feto-placental unit. This balance contains three 
successive immunological phases. The first is a strong 
inflammatory response during the implantation, the pla-
centation and the first quarter of pregnancy. Then, arises 
an anti-inflammatory phase, with a Th2 type strong 
response to assure the mother-fetus symbiosis and fetus 
development. Pregnancy maintenance is dependent on 
this cytokine profile with CD4+ cells secreting IL-4, IL-5, 
IL-6, IL-10, and IL-13 cytokines [17]. Finally, the partu-
rition requires a strong pro-inflammatory response to 
induce the uterine contractions. Th1 lymphocytes pro-
duce mainly IL-12, IFN-γ, and TNF-β that stimulate 
the production of prostaglandins and metalloproteases, 
leading to delivery [18]. This balance of the Th1/Th2 
responses is essential to pregnancy, but leads pregnant 
woman more susceptible to infections, including malaria.
Adult women living in malaria endemic areas have 
acquired a protective immunity to the repertoire of the 
P. falciparum variants they have been previously infected 
with. During pregnancy, their susceptibility to malaria 
infection increases. In areas of stable malaria transmis-
sion, this increase in susceptibility is parity-dependent, 
being highest in primigravidae. Several hypotheses have 
been suggested to explain this. Pregnant women would 
be more attractive to Anopheles and thus more bitten by 
mosquitoes than non-pregnant women [19]. Increased 
susceptibility has also been explained by the immu-
nomodulation related to the Th1/Th2 immune response 
imbalance. The increase of plasma factors, such as corti-
sol and prolactine, can inhibit the inflammatory response 
necessary for the control of the parasites [18]. However, 
none of these observations explain the higher prevalence 
of malaria in primigravidae, nor the elective localization 
of iE in the placenta [20]. The identification of VAR2CSA 
variants allowed emitting a new hypothesis. The emer-
gence of a pregnancy-specific variant corresponds to 
the parasite adaptation in its ability to bind CSA, a new 
receptor present at the surface of the ST of the placenta. 
The lack of previously—acquired specific immunity for 
this new variant antigen allows the development of the 
infection [6].
Epidemiological and immunological features of malaria 
infection during early pregnancy are almost completely 
unknown, as in most malaria endemic countries women 
first attend to maternity wards at a late gestational age, 
usually in the second half of second trimester. At the 
placental level, IE binding promotes intense infiltra-
tion of immune cells [21, 22] in the intervillous spaces, 
resulting in an important pro-inflammatory cytokines 
production necessary to parasite elimination, but harm-
ful to pregnancy. The placental inflammation promotes 
placental lesions and exchanges imbalance that are del-
eterious for intrauterine fetal growth [11, 23]. Disrup-
tion of angiogenesis through elevated levels of sFlt-1 (or 
sVEFGR1) in the second trimester has been also reported 
[24]. The building of the vascular network is mediated 
by the VEGF protein, a pro-angiogenic factor expressed 
by trophoblast that can bind to its receptor, sFlt-1, and 
inhibit its activity. The consequences of this local inflam-
mation are maternal anemia, in utero growth retardation 
and trans-placental transfer of soluble antigens to the 
fetus [23]. ST shapes local immunity by recruiting mono-
nuclear cells from the peripheral blood. Immune balance 
aims towards Th1 cytokines, such as TNF and IFN-γ. Yet, 
in primigravidae, TNF-α and IFN-γ increase correlates 
with severe anaemia and low birth weight [25]. Activated 
macrophages produce IL-1, IL-6, TNF and free radicals 
that engender placental changes, and disturb the mother-
fetal exchanges [26]. To protect ST, anti-inflammatory 
cytokines, such as IL-10, are increased [27].
In the peripheral blood, high concentrations of plas-
matic IL-10, TNF and G-CSF induce an inflammatory 
response [28]. In asymptomatically infected pregnant 
women, parasite density is correlated to the levels of 
soluble mediators of inflammation, such as soluble TNF 
receptors (TNF-R1 and TNF-R2), IL-10 and G-CSF, 
suggesting these factors may represent markers of 
PAM-related inflammation [28, 29]. Altered DCs and 
monocytes, and reduced frequency and low expression of 
the CD86 and CD80 activation markers, are observed in 
malaria-infected pregnant women, suggesting DC migra-
tion to lymphoid organs [30]. Hemozoin, the malaria 
pigment, may induce DC activation and maturation via 
the expression of CD80, CD86 and chemokine receptors 
CXCR4, promoting their migration to lymphoid organs 
[31].
The development of specific humoral immunity to 
VAR2CSA tries to limit the influx of inflammatory cells. 
During successive pregnancies, women develop specific 
immune memory against VAR2CSA variants, and acquire 
protective immunity. Multigravidae possess antibodies 
against VAR2CSA that efficiently inhibit the adhesion 
of iE to ST. The presence of anti-VAR2CSA antibodies 
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at a high titre from early pregnancy until term allows to 
protect women from placental infection [32]. Antibodies 
against VAR2CSA are essential in the elimination of the 
parasites, and the level of antibodies allows to estimate 
the level of immune protection against placental malaria 
[33]. Primigravidae exposed to P. falciparum are able, 
from the first quarter of pregnancy, to produce these spe-
cific antibodies, but to a low level, insufficient to confer 
effective protection against malaria [34].
Currently, numerous biomarkers, mainly inflamma-
tory markers, have been studied in the context of PAM. 
A systematic review of the topic reported that all these 
biomarkers were unspecific and none shown a significant 
advantage as single biomarker [35]. However, a combina-
tion of multiple biomarkers involved in different patho-
physiological pathways of PAM may increase specificity, 
and could have the needed diagnostic value to identify 
at-risk patients. Other pathologies leading to fetal growth 
restriction have been much more extensively studied 
than PAM. In these, biomarkers indicative of placenta 
dysfunction have been identified and may be of interest 
in the context of PAM. A biomarker of placenta dysfunc-
tion, even if not specific to malaria, but associated with a 
positive thick smear or RDT could determine the women 
most at risk of complications. One of the most exten-
sively studied among such pathologies is preeclampsia 
that shares numerous pathophysiological features with 
PAM.
Similarities between PAM and preeclampsia
Preeclampsia is due to a placental dysfunction that 
releases in the maternal circulation substances (free radi-
cals) causing an endothelium infringement. There are 
epidemiologic similarities between PAM and preeclamp-
sia, both being more frequent in primigravidae [36], and 
a major cause of maternal mortality in developing coun-
tries [36, 37]. Some authors described similar seasonal 
changes in the incidence of both preeclampsia and PAM, 
with increased incidence during the rainy season [38, 39]. 
Clinically, reduced placental perfusion is a common link 
between these pathologies that are associated with fetal 
growth restriction [10, 40]. Indeed, preeclampsia trans-
lates into a high arterial blood pressure, a glomerular 
renal disease with proteinuria, and can be complicated by 
lung edema, renal insufficiency, and eclampsia. Placen-
tal dysfunction is the consequence of an immunological 
imbalance that originates a deficit of the vascular reshap-
ing of maternal arteries during the trophoblastic invasion 
by extravillous cytotrophoblasts (EVCT). An excessive 
activation of the maternal immune response impairs the 
recognition of trophoblastic cells and their lysis. The 
defect of placental vascularization causes a decrease of 
blood flow in the intervillous spaces, gradually leading 
to chronic hypoxia. The oxidative stress increases apop-
totic fragments of the ST, and different factors (free radi-
cals, oxidized lipids, cytokines, sFlt-1, s-Endoglin) are 
released in the maternal circulation where they damage 
the endothelium. During preeclampsia, sFlt-1 levels are 
increased, and VEGF levels are significantly decreased 
[41]. Several reports suggest that an inflammatory reac-
tion, and an abnormal secretion of secondary cytokines 
during placental malaria might be initiators of severe 
preeclampsia and eclampsia [42–44].
Several preeclampsia biomarkers have been described 
to detect patients at risk. sFlt-1, the soluble receptor of 
VEGF having an anti-angiogenic effect, is increased in 
the peripheral blood, and its level correlated with the 
severity of the preeclampsia syndrome [45]. High con-
centrations of sFlt-1 disturb angiogenesis, even wors-
ened by elevated maternal blood levels of s-Endoglin. 
This trans-membrane anti-angiogenic glycoprotein is 
also increased in the maternal blood in the second quar-
ter of pregnancy [46]. Levine et al. [47] reported a mean 
sFlt-1 value three times higher in women with preec-
lampsia than in normal pregnancies. Women with sub-
sequent preeclampsia had twice higher concentrations 
of sFlt-1 at 16–20 weeks than the controls [24]. Placental 
protein 13 (PP13) is also increased in preeclampsia [48], 
whereas Pregnancy-associated plasma protein A (PAPP-
A) glycoprotein synthesized by the placenta is decreased. 
The placenta is also a source of circulating inflammatory 
cytokines, chemokines or immunoglobulins like IFN-γ, 
MCP-1 and ICAM-1, VCAM-1 [49], as well as TNF in 
the third quarter of pregnancy are increased in patients 
with preeclampsia [50]. Inhibin A, involved in gonado-
tropin repression, is also increased in preeclampsia. Con-
versely, the level of visfatin, a placental factor involved in 
glucose homeostasis, is decreased in the maternal blood 
[45].
Several molecules are increased in plasma during PAM, 
including ferritin with anti-inflammatory functions, as 
well as leptin and IFN-γ. An increase of IL10, that has 
an anti-inflammatory role and a negative feedback on 
TNF, has specificity and sensibility of placental inflam-
mation in PAM [51]. The immune response to CSA-bind-
ing iE involves TNF and its receptors TNF-R1 and R2. 
They stimulate the phagocytic activity of leukocytes by 
increasing ICAM-1 expression and the pro-inflammatory 
response by favouring the liberation of IL6 and IL8 [51]. 
Other biomarkers have been described as increased in 
the peripheral blood during PAM: IL1, IL10, TNF, TNF-
R1, TNF-R2 and IFN-γ [52, 53].
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Similarities between PAM and preeclampsia are 
striking and could lead to define biomarkers identified 
within the framework of preeclampsia as PAM’s poten-
tial markers. Indeed, several markers are increased in 
both pathologies, including TNF, IFN-γ, ICAM-1, IL10, 
and IL6, but those are lacking specificity. Other factors, 
such as nitric oxide synthase, s-endoglin, or TGF-ß 
soluble receptor are associated to preeclampsia, but 
also to severe malaria in children and in infected primi-
gravidae [44]. This oxidative stress has been reported 
in several placental disorders, pregnancy pathologies, 
and also in PAM [54, 55]. Malondialdehyde (MDA) 
is correlated positively with parasitaemia and NO is 
correlated negatively with birth weight [55]. sFlt-1 is 
also increased during PAM and associated with fetal 
loss, intra-uterine growth restriction, and placental 
inflammation.
Duffy’s study reported a correlation between PAM and 
hypertension in young primigravidae. In this population, 
levels of sFlt-1 are elevated, suggesting its involvement in 
this correlation [42]. These similarities between malaria 
infection and preeclampsia open additional horizons. All 
these biomarkers are thus potential candidates for the 
diagnosis of PAM with placental damage, but have not 
been validated in clinical practice. A randomized study 
may allow validating their interest to improve the detec-
tion of a suffering placenta as a consequence of malaria 
infection.
Preeclampsia screening involves monthly blood pres-
sure and proteinuria check. The diagnosis is made 
after 20 gestational weeks if the blood pressure is more 
than 14/10  mm/hg and proteinuria  >0.3  g/24  h. Actu-
ally, new ways of detection are studied, adding to these 
measures the uterine Doppler and the PlGF and sFlt-1 
dosages. Combined they should identify, in the third 
trimester, 84% of preeclampsia with 10% of false posi-
tive [56]. Indeed, the biomarkers can help to the screen-
ing of women at risk of preeclampsia. But this has to be 
confirmed. In France, numerous laboratories work on 
this hypothesis that is not currently included as stand-
ard practice, only blood pressure and urine protein 
test being part of the monitoring during prenatal con-
sultations. Moreover, there are suspicions (although 
this is not clearly demonstrated) that malaria during 
pregnancy is a risk factor for preeclampsia, most prob-
ably through placental alterations. In a malaria-endemic 
area, it is certainly difficult to manage preeclampsia, but 
women presenting an sFlt-1/PlGF high level should be 
submitted to protein urinary stick and blood pressure 
measurement.
Conclusion
Identification of patients at risk of poor pregnancy out-
come thanks to biomarkers will allow to optimize the 
prevention of the consequences of placental sequestra-
tion. Currently, the management of PAM, by long-lasting 
insecticide-impregnated nets (LLIN) and intermittent 
preventive treatment in pregnancy, occurs often late, 
and is taking care of malaria infection but not of its con-
sequences on the placenta that may persist after having 
cure the infection. It seems clear that the availability of a 
tool to identify, at an early stage, a placenta ‘under stress’ 
resulting from PAM would represent an important step 
forward in terms of diagnosing and treating one of the 
main causes of poor pregnancy outcomes in African 
populations. Such biomarker would help in understand-
ing the relationships between the timing and severity of 
P. falciparum infections and poor pregnancy outcomes, 
and to optimize preventive and curative interventions. A 
biomarker of placenta dysfunction along with a positive 
thick smear or RDT, should evidence a suffering placen-
tal. This screening test would allow to add to IPT a regular 
monitoring during the pregnancy with a more appropri-
ated treatment. It would be a primary tool to predict poor 
pregnancy outcomes, to adapt monitoring, and to ensure 
a close clinical and sonographic surveillance of these 
patients (Fig. 1). PAM increases the risk of preterm deliv-
ery by the secretion of cytokines, and the risks of IUGR by 
chronic hypoxia of the fetus. The identification of women 
at risk would allow the initiation of curative treatment 
during the pregnancy by artemisinin-based combination 
therapy (ACT) [57]. If the patients have severe malaria, 
treatment with artesunate IV is recommended in comple-
ment with paracetamol to limit the hyperthermia. In case 
of severe anaemia (Hb <7 g/dl), blood transfusion will be 
needed [57]. An echography to estimate the fetal weight, 
with Doppler measure could be realised at the begin-
ning of treatment, and at 15 days intervals. The Doppler 
will allow to evaluate the level of placental alterations. 
Indeed, the Doppler allows, in function of the gestational 
age, to evaluate the benefice to follow-up the pregnancy 
in case of severe IUGR [58, 59]. Additionally, variations 
in the biomarker level could have a prognostic value for 
the surveillance of placenta stress evolution. Of course, 
these prerogatives cannot be currently implemented in 
all health centres in malaria transmission areas. However, 
things are moving fast, and ultrasound apparatus are now 
available in an increasing number of health centres in 
tropical areas. The goal is also to improve the surveillance 
of pregnancies, access to screening, to treatments, and the 
evaluation of the fetal health by Doppler echography.
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